CT Based Assessment of Sarcopenia and Its Association With Biologic Treatment Outcomes in Inflammatory Bowel Disease Patients

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07482163

Acronym

Sarcopenia/IBD

Enrollment

Registered

2026-03-19

Start date

2026-05-01

Completion date

2028-05-01

Last updated

2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CT-Assessed Sarcopenia Outcomes

Brief summary

Our study aims to investigate the incidence of sarcopenia in Patients with IBD using CT-based body composition parameters, observe the interaction between sarcopenia and IBD treatment, and determine whether sarcopenia affects the response to biologic therapies

Detailed description

Inflammatory bowel disease (IBD) has a relapsing-remitting course which necessitates frequent follow-up examinations to monitor disease activity. Disease management was previously guided by patient reported symptoms, and treatment targets were based on symptom control. However, the patient's symptoms do not necessarily correspond to inflammatory activity and current guidelines recommend that management should be based on objective evaluations. Due to reduced food intake, intestinal malabsorption, chronic protein loss through the feces, and increased energy demands from hypermetabolism , patients with IBD may suffer from malnutrition, and sarcopenia, even during remission. In 2014, the Asian Working Group forSarcopenia defined sarcopenia as an age-related decline in skeletal muscle mass as well as muscle function (defined by muscle strength or physical performance). Sarcopenia has been associated with older age, but it is also a known complication of various chronic diseases, such as cirrhosis, intestinal disorders, chronic kidney disease, neurodegenerative diseases, and malignant tumors . Sarcopenia affects the prognosis of IBD and is recognized as a risk factor for surgery, hospitalization, and postoperative complications in patients with IBD. Skeletal muscle mass can be assessed using various methods, including bioelectrical impedance analysis (BIA) , dual-energy X-ray absorptiometry (DXA), computed tomography (CT), and magnetic resonance imaging (MRI). However each technique exhibits considerable variability and lacks established reference standards. The total skeletal muscle area measured by CT or MRI at the L3-L4 lumbar spine levels is regarded as the gold standard for assessing skeletal muscle mass. CT enterography (CTE) is a routine diagnostic procedure for and can be utilized to evaluate their skeletal muscle mass without the need for additional tests.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Patient above age of 18 years old * diagnosed to have IBD through: clinical features, endoscopic findings * received biological therapy

Exclusion criteria

* Patients with UC who are under age of 18 years old. * Pregnancy. * Previous colectomy. * Patient refuse to participate in the study

Design outcomes

Primary

Measure	Time frame	Description
Incidence of Sarcopenia in Inflammatory Bowel Disease Patients	At base line	To determine the incidence of sarcopenia in patients with inflammatory bowel disease using computed tomography (CT)-based body composition analysis, including skeletal muscle index (SMI) measured at the level of the third lumbar vertebra (L3), expressed in cm²/m².

Contacts

CONTACTAmira M. Abdelmawgod, MD, Assuit University

amiramohmad60@gmail.com+201012760437

Outcome results